Projected Impact of Omidubicel-onlv on Racial/Ethnic Disparities in Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Outcomes in Hematologic Malignancies.
Allogeneic hematopoietic cell transplant
Healthcare equity
Hematologic malignancies
Omidubicel-onlv
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
01 Mar 2024
01 Mar 2024
Historique:
received:
02
11
2023
accepted:
14
12
2023
medline:
1
3
2024
pubmed:
1
3
2024
entrez:
1
3
2024
Statut:
aheadofprint
Résumé
In a phase III clinical trial (NCT02730299), omidubicel-onlv, a nicotinamide-modified allogeneic hematopoietic progenitor cell therapy, showed rapid hematopoietic and immune recovery compared with standard umbilical cord blood (UCB) transplant across all racial/ethnic groups. A decision-tree model was used to project the effect of omidubicel-onlv availability on addressing health disparities in allogeneic hematopoietic cell transplantation (allo-HCT) access and outcomes for patients with hematologic malignancies. The model used a hypothetical population of 10,000 allo-HCT-eligible US adults, for whom matched related donors were not available. Patients received matched or mismatched unrelated donor, haploidentical, UCB transplant, or no transplant. Scenarios with omidubicel-onlv use of 0% (status quo), 10%, 15%, 20%, and 30% were modeled on the basis of proportional reductions in other allo-HCT sources or no transplant by racial/ethnic group. Increased omidubicel-onlv use was associated with a higher proportion of patients undergoing allo-HCT, decreased time to allo-HCT, decreased 1-year non-relapse mortality, and increased 1-year overall survival, particularly among racial minorities. In the scenario modeling 20% omidubicel-onlv use, the proportion of Black patients receiving allo-HCT increased by 129%; increases were also observed in Asian (64%), Hispanic (45%), and other (42%) patient groups. Modeled time to allo-HCT improved among transplanted patients (23%) from 11.4 weeks to 8.8 weeks. One-year OS in the overall population increased by 3%, with improvements ranging from 3% for White patients to 5% for Black patients. This study demonstrates that broad access to omidubicel-onlv could increase access to allo-HCT and improve outcomes for patients, with the greatest benefits seen among racial/ethnic minority groups.
Identifiants
pubmed: 38427220
doi: 10.1007/s12325-023-02771-z
pii: 10.1007/s12325-023-02771-z
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
© 2024. The Author(s).
Références
National Marrow Donor Program: Be the Match. Disease-specific HCT indications and outcomes data. https://bethematchclinical.org/transplant-indications-and-outcomes/disease-specific-indications-and-outcomes/ . Accessed June 15, 2021.
Kekre N, Antin JH. Hematopoietic stem cell transplantation donor sources in the 21st century: choosing the ideal donor when a perfect match does not exist. Blood. 2014;124:334–43.
doi: 10.1182/blood-2014-02-514760
pubmed: 24914138
Howard CA, Fernandez-Vina MA, Appelbaum FR, et al. Recommendations for donor human leukocyte antigen assessment and matching for allogeneic stem cell transplantation: consensus opinion of the blood and marrow transplant clinical trials network (BMT CTN). Biol Blood Marrow Transplant. 2015;21:4–7.
doi: 10.1016/j.bbmt.2014.09.017
pubmed: 25278457
Gragert L, Eapen M, Williams E, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med. 2014;371:339–48.
doi: 10.1056/NEJMsa1311707
pubmed: 25054717
pmcid: 5965695
Eapen M, Rocha V, Sanz G, et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol. 2010;11:653–60.
doi: 10.1016/S1470-2045(10)70127-3
pubmed: 20558104
pmcid: 3163510
Fingrut WB, Gyurkocza B, Davis E, et al. Racial disparities in access to alternative donor allografts persist in the era of “donors for all.” Blood Adv. 2022;6:5625–9.
doi: 10.1182/bloodadvances.2022007814
pubmed: 35675518
pmcid: 9642869
Kosuri S, Wolff T, Devlin SM, et al. Prospective evaluation of unrelated donor cord blood and haploidentical donor access reveals graft availability varies by patient ancestry: practical implications for donor selection. Biol Blood Marrow Transplant. 2017;23:965–70.
doi: 10.1016/j.bbmt.2017.03.001
pubmed: 28263918
pmcid: 9370627
Landry I. Racial disparities in hematopoietic stem cell transplant: a systematic review of the literature. Stem Cell Investig. 2021;8:24.
doi: 10.21037/sci-2021-058
pubmed: 35071585
pmcid: 8743384
Ballen KK, Klein JP, Pedersen TL, et al. Relationship of race/ethnicity and survival after single umbilical cord blood transplantation for adults and children with leukemia and myelodysplastic syndromes. Biol Blood Marrow Transplant. 2012;18:903–12.
doi: 10.1016/j.bbmt.2011.10.040
pubmed: 22062801
Pulte D, Redaniel MT, Jansen L, Brenner H, Jeffreys M. Recent trends in survival of adult patients with acute leukemia: overall improvements, but persistent and partly increasing disparity in survival of patients from minority groups. Haematologica. 2013;98:222–9.
doi: 10.3324/haematol.2012.063602
pubmed: 22929974
pmcid: 3561429
Baker KS, Loberiza FR Jr, Yu H, et al. Outcome of ethnic minorities with acute or chronic leukemia treated with hematopoietic stem-cell transplantation in the United States. J Clin Oncol. 2005;23:7032–42.
doi: 10.1200/JCO.2005.01.7269
pubmed: 16145067
Khera N, Hahn TE, Brazauskas R, et al. Trends in use and outcomes of autologous and allogeneic hematopoietic cell transplantation in racial/ethnic minorities. Blood. 2021;138:427.
doi: 10.1182/blood-2021-146967
Mielcarek M, Gooley T, Martin PJ, et al. Effects of race on survival after stem cell transplantation. Biol Blood Marrow Transplant. 2005;11:231–9.
doi: 10.1016/j.bbmt.2004.12.327
pubmed: 15744242
Barker JN, Kurtzberg J, Ballen K, et al. Optimal practices in unrelated donor cord blood transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2017;23:882–96.
doi: 10.1016/j.bbmt.2017.03.006
pubmed: 28279825
pmcid: 5543989
Horwitz ME, Stiff PJ, Cutler C, et al. Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study. Blood. 2021;138:1429–40.
doi: 10.1182/blood.2021011719
pubmed: 34157093
pmcid: 9710469
Horwitz ME, Wease S, Blackwell B, et al. Phase I/II study of stem-cell transplantation using a single cord blood unit expanded ex vivo with nicotinamide. J Clin Oncol. 2019;37:367–74.
doi: 10.1200/JCO.18.00053
pubmed: 30523748
Horwitz ME, Chao NJ, Rizzieri DA, et al. Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment. J Clin Invest. 2014;124:3121–8.
doi: 10.1172/JCI74556
pubmed: 24911148
pmcid: 4071379
Peled T, Shoham H, Aschengrau D, et al. Nicotinamide, a SIRT1 inhibitor, inhibits differentiation and facilitates expansion of hematopoietic progenitor cells with enhanced bone marrow homing and engraftment. Exp Hematol. 2012;40:342–55.
doi: 10.1016/j.exphem.2011.12.005
pubmed: 22198152
Auletta JJ, Kou J, Chen M, et al. Real-world data showing trends and outcomes by race and ethnicity in allogeneic hematopoietic cell transplantation: a report from the Center for International Blood and Marrow Transplant Research. Transplant Cell Ther. 2023;29:346.
doi: 10.1016/j.jtct.2023.03.007
OMISERGE prescribing information. April 2023. https://www.fda.gov/media/167202/download . Accessed May 22, 2023.
National Marrow Donor Program, a contractor for the C.W. Bill Young Cell Transplantation Program operated through the U.S. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau. Donor registry transplant data. Last updated: April 14, 2022.
U.S. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau. The need for more marrow donors. https://bloodstemcell.hrsa.gov/donor-information/donate-bone-marrow/need-more-marrow-donors . Accessed Apr 15, 2022.
Ciurea SO, Bittencourt MCB, Milton DR, et al. Is a matched unrelated donor search needed for all allogeneic transplant candidates? Blood Adv. 2018;2:2254–61.
doi: 10.1182/bloodadvances.2018021899
pubmed: 30206098
pmcid: 6134218
Mayani H, Wagner JE, Broxmeyer HE. Cord blood research, banking, and transplantation: achievements, challenges, and perspectives. Bone Marrow Transplant. 2020;55:48–61.
doi: 10.1038/s41409-019-0546-9
pubmed: 31089283
Brunstein CG, Fuchs EJ, Carter SL, et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood. 2011;118:282–8.
doi: 10.1182/blood-2011-03-344853
pubmed: 21527516
pmcid: 3138683
Matthews AH, Perl AE, Luger SM, et al. Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia. Blood Adv. 2022;6:3997–4005.
doi: 10.1182/bloodadvances.2022007265
pubmed: 35507945
pmcid: 9278286
Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the international ALL trial (MRC UKALL XII/ECOG E2993). Blood. 2008;111:1827–33.
doi: 10.1182/blood-2007-10-116582
pubmed: 18048644
Baker M, Wang H, Rowley SD, et al. Comparative outcomes after haploidentical or unrelated donor bone marrow or blood stem cell transplantation in adult patients with hematological malignancies. Biol Blood Marrow Transplant. 2016;22:2047–55.
doi: 10.1016/j.bbmt.2016.08.003
pubmed: 27522040
Szabolcs P, Mazor RD, Yackoubov D, et al. Immune reconstitution profiling suggests antiviral protection after transplantation with omidubicel: a phase 3 substudy. Transplant Cell Ther. 2023;29:517.e1-517.e12.
doi: 10.1016/j.jtct.2023.04.018
pubmed: 37120136
Shaw BE, Jimenez-Jimenez AM, Burns LJ, et al. National Marrow Donor Program-sponsored multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide. J Clin Oncol. 2021;39:1971–82.
doi: 10.1200/JCO.20.03502
pubmed: 33905264
pmcid: 8260905
Shaw BE, Jimenez-Jimenez AM, Burns LJ, et al. Three-year outcomes in recipients of mismatched unrelated bone marrow donor transplants using post-transplanation cyclophosphamide: follow-up from a National Marrow Donor Program-sponsored prospective clinical trial. Transplant Cell Ther. 2023;29:208.
doi: 10.1016/j.jtct.2022.12.017
Malki MMA, Devine SM, Shaw BE, et al. Access: a multi-center, phase II trial of HLA-mismatched unrelated donor hematopoietic cell transplantation with post-transplantation cyclophosphamide for patients with hematologic malignancies. Blood. 2022;140(suppl 1):7591–3.
doi: 10.1182/blood-2022-162581
National Marrow Donor Program: Be The Match. National Marrow Donor Program/Be The Match announce plan to launch ACCESS clinical trial: assessing HLA-mismatched unrelated donor hematopoietic cell transplantation with post-transplantation cyclophosphamide [press release]. 2021. https://bethematch.org/news/news-releases/national-marrow-donor-program/be-the-match-announce-plan-to-launch-access-clinical-trial/ . Accessed 15 Dec 2022.
Auletta JJ, Sandmaier BM, Jensen E, et al. The ASTCT-NMDP ACCESS Initiative: a collaboration to address and sustain equal outcomes for all across the hematopoietic cell transplantation and cellular therapy ecosystem. Transplant Cell Ther. 2022;28:802–9.
doi: 10.1016/j.jtct.2022.09.020
pubmed: 36184058
Cutler C, Kim HT, Sun L, et al. Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood. 2011;118:6691–7.
doi: 10.1182/blood-2011-05-355263
pubmed: 21940825
pmcid: 3976219
Shpall EJ, Rezvani K. Cord blood expansion has arrived. Blood. 2021;138:1381–2.
doi: 10.1182/blood.2021012725
pubmed: 34673952